<DOC>
	<DOCNO>NCT01132495</DOCNO>
	<brief_summary>The overall purpose FAME II trial compare clinical outcome , safety cost-effectiveness FFR-guided PCI plus optimal medical treatment ( OMT ) versus OMT alone patient stable coronary artery disease .</brief_summary>
	<brief_title>FAME II - Fractional Flow Reserve ( FFR ) Guided Percutaneous Coronary Intervention ( PCI ) Plus Optimal Medical Treatment ( OMT ) Verses OMT</brief_title>
	<detailed_description>Prospective , multi-center , multi-national , multi-continental , randomized clinical trial .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>1 . Patients stable angina , stabilize angina pectoris , atypical chest pain chest pain document silent ischemia 2. least one stenosis present least 50 % one major native epicardial coronary artery supply viable myocardium 3 . Eligible PCI 4 . Signed write informed consent 1 . Patients preferred treatment CABG 2 . Patients leave main coronary artery disease require revascularization 3 . Patients recent STEMI NonSTEMI 4 . Prior CABG 5 . Contraindication dual antiplatelet therapy 6 . LVEF &lt; 30 % 7 . Severe LV hypertrophy 8 . Planned need concomitant cardiac surgery 9 . Extremely tortuous calcify coronary artery preclude FFR measurement 10 . A life expectancy le 2 year 11 . Age 21</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Stable angina</keyword>
	<keyword>angina pectoris</keyword>
	<keyword>PCI</keyword>
	<keyword>FAME</keyword>
	<keyword>FAME II</keyword>
	<keyword>FFR</keyword>
	<keyword>Fractional Flow Reserve</keyword>
	<keyword>Pressure wire</keyword>
</DOC>